Description

Swiss Pharmaceuticals Goralatide 250 mcg – 60 Capsules is listed as 250 mcg per capsule in a package of 60 capsules. This is a neutral product-information and regulatory-review draft, not medical advice or proof of authorisation.

Retailer information describes the product as goralatide acetate at 250 mcg per capsule, with 60 capsules. Goralatide is the tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline, abbreviated Ac-SDKP. The precise salt form, peptide purity, acetate contribution, inactive ingredients, and oral stability require confirmation.

Reported Product Profile

What Is Goralatide (Ac-SDKP)?

Ac-SDKP is an endogenous peptide fragment generated from the amino-terminal region of thymosin beta-4. It is present naturally in biological systems and has been investigated as a regulator of haematopoiesis, fibrosis, inflammation, angiogenesis, and tissue responses. It remains an experimental substance rather than a conventional nutritional ingredient.

How It Works

Early research identified Ac-SDKP as a negative regulator of primitive haematopoietic stem and progenitor-cell proliferation. It can reduce entry of certain normal cells into the DNA-synthesis phase of the cell cycle, temporarily maintaining them in a more quiescent state. Ac-SDKP is also a natural substrate of the amino-terminal catalytic domain of angiotensin-converting enzyme, which helps regulate its concentration.

Later research has explored anti-fibrotic, anti-inflammatory, and angiogenic pathways, but these findings come largely from cellular, animal, and specialised experimental models. A mechanism involving stem-cell quiescence is not equivalent to general immune support or faster recovery. It may also have different implications depending on disease, medication, and treatment context.

Evidence and Product Limitations

Published studies have examined whether goralatide can protect normal haematopoietic progenitors during chemotherapy, radiation, or hyperthermia and have investigated cardiovascular and renal fibrosis. These studies do not establish the safety, absorption, or clinical effectiveness of a 250 mcg oral capsule sold online. No authorised indication for this specific product has been confirmed.

Peptides may be degraded by digestive enzymes, and the systemic exposure achieved from an ordinary capsule is unknown. Product documentation should include sequence confirmation, mass spectrometry, chromatographic purity, acetate content, dissolution and stability testing, microbiological results, and evidence supporting the claimed route of administration.

Safety and Regulatory Considerations

The clinical safety profile of unsupervised oral goralatide is not established. Altering haematopoietic, inflammatory, angiogenic, or fibrotic signalling could have context-dependent consequences. Potential interactions with ACE inhibitors are scientifically relevant because those medicines can increase endogenous Ac-SDKP concentrations. Patients receiving cancer treatment, immunosuppressive therapy, or cardiovascular medicines require professional review.

Goralatide is an experimental pharmacologically active peptide. It should not be presented as a food supplement or therapeutic product without evidence of lawful classification and product-specific authorisation. Retailer language does not establish regulatory approval.

Information for Athletes

Athletes should regard experimental peptide products as high risk because purity and composition are uncertain. Even when a peptide is not named individually, undeclared prohibited hormones, growth factors, or related agents may be present.

Important: No dosage, cycle, treatment, or guaranteed-benefit guidance is provided. Confirm identity, purity, composition, and lawful supply for the specific batch.